Cervical Dystonia Management Market Size, Share, Growth, Trends, and Global Industry Analysis: By Administration (Oral, Intravenous), By Drug Class (Dopaminergic drugs, Anti-cholinergic drugs, GABA Agonists, Anti Convulsants), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Others), and Region Forecast 2020-2031

Cervical Dystonia Management Market size was valued at US$ 119.8 million in 2024 and is expected to reach US$ 168.6 million by 2031, growing at a significant CAGR of 5% from 2025-2031. Cervical dystonia, also known as spasmodic torticollis, rare neurological disorder that originates in the brain. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect the quality of life and activities of daily living including employment.

Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood. The cause of cervical dystonia is unknown, although a genetic susceptibility is thought to underlie some cases. According to the Association of neurological American Surgeons about 250,000 people are having cervical dystonia every year. According to National organization for rare diseases (NORD) it is anticipated that around 60,000 individuals in US are suffering with cervical dystonia.

Key Developments:

• In March, 2019, Ipsen Biopharmaceuticals Inc., the Canadian affiliate of Ipsen has received Health Canada approval for DYSPORT THERAPEUTIC (abobotulinumtoxinA) to treat cervical dystonia.
• In 2019, Merz Pharmaceuticals received USFDA approval fo Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm.